dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | Velez, L |
dc.contributor.author | Trevino, T. L. |
dc.contributor.author | Grothey, Axel |
dc.contributor.author | Van Cutsem, Eric |
dc.contributor.author | Yaeger, Rona |
dc.date.accessioned | 2022-06-28T10:37:05Z |
dc.date.available | 2022-06-28T10:37:05Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R, Van Cutsem E, et al. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open. 2021 Dec;6(6):100328. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/7739 |
dc.description | Esdeveniments adversos; Cetuximab; Encorafenib |
dc.description.sponsorship | This work was supported by Array BioPharma in collaboration with Merck KGaA Darmstadt, Germany (for sites outside of North America), ONO Pharmaceutical, Japan, and Pierre Fabre, France. Array BioPharma was acquired by Pfizer in July 2019. This work was also supported by the Cancer Center Core [grant number P30 CA 008748] to MSKCC. Medical writing/editorial support was provided by Namiko Abe, PhD, and Alyson Bexfield, PhD, of Caudex, New York, and was funded by Pfizer. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;6(6) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments - Efectes secundaris |
dc.subject | Còlon - Càncer - Tractament |
dc.subject | Recte - Càncer - Tractament |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /adverse effects |
dc.title | Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2021.100328 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2021.100328 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Tabernero J, Velez L] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVIC-UCC, IOB-Quiron, Barcelona, Spain. [Trevino TL] Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. [Grothey A] West Cancer Center and Research Institute, OneOncology, Germantown, USA. [Yaeger R] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA. [Van Cutsem E] Digestive Oncology Department, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium |
dc.identifier.pmid | 34896698 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |